Warren Hsu, DO
Allergy · Oakland Gardens, NYNPI 1053473843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 44.5% of the total. Reporting peaked in 2023 at $1,043 and has fallen 84.0% since, to $167 in 2024.
Across 110 payments — averaging $32.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$405
- Gilead$301
- Regeneron Healthcare Solutions, Inc.$223
- Sanofi$205
- AbbVie$189
- plus $690 from 10 others
What the payments were for
- Food & beverage$3,626100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $1,614 |
| GSK | 16 | $405 |
| Gilead | 13 | $301 |
| Regeneron Healthcare Solutions, Inc. | 6 | $223 |
| Sanofi | 4 | $205 |
| AbbVie | 11 | $189 |
| Kowa Pharmaceuticals America, Inc. | 13 | $175 |
| Amgen(2 entities) | 3 | $156 |
| Johnson & Johnson | 1 | $125 |
| Merck | 5 | $97 |
| Oyster Point Pharma, Inc. | 2 | $39 |
| Lilly USA, LLC | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Kaleo, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,626 in reported general payments places this provider in the 60th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 26 | $14,574 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 12 | $1,592 |
| Rosuvastatin Calcium | 72 | $1,312 |
| Fluticasone Propionate | 23 | $619 |
| Tamsulosin Hcl | 26 | $581 |
| Atorvastatin Calcium | 90 | $552 |
| Telmisartan | 23 | $548 |
| Amlodipine Besylate | 75 | $522 |
| Losartan Potassium | 39 | $420 |
| Metoprolol Succinate | 17 | $373 |
| Levothyroxine Sodium | 14 | $239 |
| Metformin Hcl ErMetformin Hcl | 22 | $230 |
| Metformin Hcl | 13 | $228 |
| Omeprazole | 17 | $190 |
| Sertraline Hcl | 13 | $149 |
Paid to pharmacies, not to this prescriber.
Other allergy in Oakland Gardens
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
- Alissa McInerneyAstoria$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.